Herceptest: Her2 expression and gene amplification in non‐small cell lung cancer

HER2 is an erbB/HER type 1 tyrosine kinase receptor that is frequently over‐expressed in malignant epithelial tumours. Herceptin, a humanised mouse monoclonal antibody to HER2, is proven therapeutically in the management of metastatic breast cancer, significantly prolonging survival when combined wi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2001-05, Vol.92 (4), p.480-483
Main Authors: Cox, G., Vyberg, M., Melgaard, B., Askaa, J., Oster, A., O'Byrne, K.J.
Format: Article
Language:English
Subjects:
Adenocarcinoma - metabolism
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Carcinoma, Large Cell - metabolism
Carcinoma, Non-Small-Cell Lung - metabolism
Cell Membrane - metabolism
Female
HER2
HER2 protein
herceptin
HerceptTest
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
lung carcinoma
Lung Neoplasms - metabolism
Male
Medical sciences
Neoplasms, Squamous Cell - metabolism
non‐small‐cell lung cancer
Ploidies
Pneumology
prognosis
Receptor, ErbB-2 - biosynthesis
Retrospective Studies
Trastuzumab
Tumors of the respiratory system and mediastinum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HER2 is an erbB/HER type 1 tyrosine kinase receptor that is frequently over‐expressed in malignant epithelial tumours. Herceptin, a humanised mouse monoclonal antibody to HER2, is proven therapeutically in the management of metastatic breast cancer, significantly prolonging survival when combined with cytotoxic chemotherapeutic agents. Immunohistochemical studies suggest that non‐small‐cell lung cancer (NSCLC) tumours may over‐express HER2. Our aim was to evaluate HER2 gene amplification and semi‐quantitative immuno‐expression in NSCLC. A total of 344 NSCLC cases were immunostained for HER2 expression in 2 centres using the HercepTest. Fluorescence in situ hybridisation (FISH) analysis for HER2 gene amplification was performed on most positive cases and a subset of negative cases. Fifteen cases (4.3%) demonstrated 2+ or 3+ membranous HER2 immuno‐expression. There was no correlation between immuno‐expression and tumour histology or grade. Tumours from higher‐stage disease were more often HercepTest‐positive (p < 0.001). All 4 HercepTest 3+ cases demonstrated gene amplification. One of the 5 2+ cases tested for gene amplification showed areas of borderline amplification and areas of polyploidy. None of the 19 HercepTest‐negative cases demonstrated gene amplification or polyploidy (p < 0.001). Gene amplification was demonstrated in all HercepTest 3+ scoring NSCLC cases. Unlike breast cancer, gene amplification and HER2 protein over‐expression assessed by the HercepTest appeared to be uncommon in NSCLC. Herceptin may therefore target only a small proportion of NSCLC tumours and be of limited clinical value in this disease, particularly in the adjuvant setting. © 2001 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.1214